Condition
Serous Ovarian Tumor
Total Trials
4
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting2
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06180356Phase 2Recruiting
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression
NCT07303894Phase 2Recruiting
A Study of Isoquercetin in People With Ovarian Cancer
NCT06274541CompletedPrimary
Upfront Systematic Tumour BRCA Testing in Patients With High Grade Serous or Endometrioid Ovarian, Fallopian Tube or Primary Peritoneal Cancer (HGSEC): The t-BRCA Study
NCT03926936Phase 2Completed
FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study
Showing all 4 trials